Doses of Tepezza are given by an intravenous infusion through a blood vessel in your arm. This infusion is usually given at a hospital, health care provider’s office, or infusion center. Sometimes you ...

Credit: Shutterstock. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. The Indications and Usage section of the Tepezza ® (teprotumumab-trbw) prescribing information has been ...

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA™ (teprotumumab-trbw) showing that the ...

Credit: Getty Images. Tepezza is a human insulin-like growth factor-1 receptor inhibitor. Tepezza ® (teprotumumab-trbw) significantly reduced proptosis in adults with chronic thyroid eye disease (TED) ...

-- Highlights include a poster presentation about real-world adherence to TEPEZZA and an oral presentation sharing data from the OPTIC-X extension trial in people with Thyroid Eye Disease (TED) who ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Since its approval in 2020, Tepezza has become a go-to treatment for moderate to severe thyroid eye ...

Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this ...

Christy Bieber has a JD from UCLA School of Law and began her career as a college instructor and textbook author. She has been writing full time for over a decade with a focus on making financial and ...

As Amgen’s $27.8 billion buyout of Horizon Therapeutics became official earlier this month, one of the first orders of business for the California biotech giant was to get acquired blockbuster Tepezza ...